Table 2. Association of NLRP3 single nucleotide polymorphism with delayed graft function, primary non-function, death-censored graft survival and patient survival.
| Gene rs number | Genotype | Donor |
Recipient |
||
|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | ||
| Delayed graft function (including primary non-function) | |||||
| NLRP3 (GOF) rs35829419 | A/A (ref)A/a + a/a | 1.001.13 (0.77–1.64) | 0.53 | 1.000.72 (0.48–1.04) | 0.09 |
| NLRP3 (LOF) rs6672995 | A/A (ref)A/a + a/a | 1.001.22 (0.95–1.58) | 0.12 | 1.001.07 (0.82–1.38) | 0.64 |
| OR2B11/NLRP3 (LOF) rs4353135 | A/A (ref)A/a + a/a | 1.000.95 (0.75–1.20) | 0.64 | 1.00 | 0.54 |
| 0.93 (0.73–1.17) | |||||
| Primary non-function | |||||
| NLRP3 (GOF) rs35829419 | A/A (ref)A/a + a/a | 1.001.12 (0.46–2.37) | 0.78 | 1.001.15 (0.50–2.34) | 0.72 |
| NLRP3 (LOF) rs6672995 | A/A (ref)A/a + a/a | 1.000.89 (0.48–1.57) | 0.71 | 1.000.98 (0.53–1.72) | 0.94 |
| OR2B11/NLRP3 (LOF) rs4353135 | A/A (ref)A/a + a/a | 1.000.74 (0.44–1.25) | 0.26 | 1.001.08 (0.64–1.81) | 0.78 |
| Death-censored graft failure | |||||
| NLRP3 (GOF) rs35829419 | A/A (ref)A/a + a/a | 1.001.12 (0.74–1.70) | 0.59 | 1.000.92 (0.60–1.42) | 0.71 |
| NLRP3 (LOF) rs6672995 | A/A (ref)A/a + a/a | 1.000.97 (0.72–1.31) | 0.86 | 1.000.83 (0.61–1.15) | 0.26 |
| OR2B11 NLRP3 (LOF) rs4353135 | A/A (ref)A/a + a/a | 1.000.99 (0.76–1.30) | 0.94 | 1.001.11 (0.85–1.45) | 0.44 |
| Patient survival | |||||
| NLRP3 (GOF) rs35829419 | A/A (ref)A/a + a/a | 1.00.99 (0.64–1.52) | 0.95 | 1.01.09 (0.72–1.64) | 0.68 |
| NLRP3 (LOF) rs6672995 | A/A (ref)A/a + a/a | 1.00.79 (0.59–1.07) | 0.13 | 1.01.24 (0.93–1.66) | 0.14 |
| OR2B11 NLRP3 (LOF) rs4353135 | A/A (ref)A/a + a/a | 1.01.01 (0.78–1.32) | 0.93 | 1.01.15 (0.88–1.50) | 0.30 |
Homozygous dominant (A/A) is considered reference group (ref) and compared to heterozygous + homozygous recessive (A/a + a/a), GOF = gain of function, LOF = loss of function, OR = odds ratio, CI = confidence interval, HR = hazard ration.